EN | UA
EN | UA

Help Support

Back

NOACs are effective and safe for adults with congenital heart disease

Congenital heart disease Congenital heart disease
Congenital heart disease Congenital heart disease

What's new?

In congenital heart disease-affected adults, the use of NOACs is effective and safe.

According to the findings of a single-center retrospective analysis, novel oral anticoagulants (NOACs) are effective and safe in adults with congenital heart disease (ACHD). This study was carried out to investigate ACHD patients (median age 55 years, 57% were male) who had been receiving NOAC treatment for a minimum of three months.

The median follow-up period was seventeen months (interquartile range [IQR]: 10–41). The most popular used NOAC was Eliquis (47% usage). HAS-BLED was 1 (IQR: 0–2) and the median CHA2DS2-VASc score was 2 (IQR: 0-3). Among the patients, 27% had complex ACHD. During the 64 years of cumulative patient follow-up, no thromboembolic events were documented. However, one significant unspecified hemorrhage was noted. Hence, the use of NOACs is safe and efficient in ACHD-affected people. It is crucial to carry out more extensive research on NOAC use in ACHD patients.

Source:

The Egyptian Heart Journal

Article:

Novel oral anticoagulant use in adults with congenital heart disease: a single-center experience report

Authors:

Daniel Samarai et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: